GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

National Health Investors NHI · USD

Real Estate · US listing · 🇺🇸 United States

Compare

71.23

-0.01%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$378.5m

FY2016FY2025

Net income

$142.2m

FY2016FY2025

Free cash flow

$220.3m

FY2016FY2025

Shareholders' equity

$1.52bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$378.5m$335.2m$319.8m$278.2m$298.7m$332.8m$318.1m$294.6m$278.7m$248.5m
Research and development——$0$0$0$1$1$1$1$1
Operating income$194.8m$183.9m$178.8m$110.3m$185.3m$224.9m$220.0m$209.2m$197.8m$177.7m
Net income$142.2m$138.0m$135.7m$66.4m$111.8m$185.1m$160.5m$154.3m$159.4m$151.5m
Diluted earnings per share3.023.043.131.532.444.133.623.633.813.79

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$2.80bn$2.61bn$2.49bn$2.51bn$2.84bn$3.12bn$3.04bn$2.75bn$2.55bn$2.40bn
Cash and short-term investments$19.6m$24.3m$22.3m$19.3m$37.4m$43.3m$5.2m$4.7m$3.1m$4.8m
Total liabilities$1.26bn$1.23bn$1.21bn$1.22bn$1.32bn$1.60bn$1.54bn$1.36bn$1.22bn$1.19bn
Debt$1.29bn$1.48bn$1.38bn$1.56bn$1.32bn$1.96bn$1.44bn$1.30bn$1.17bn$1.13bn
Shareholders' equity$1.52bn$1.37bn$1.25bn$1.29bn$1.52bn$1.52bn$1.50bn$1.39bn$1.32bn$1.21bn
Shares outstanding47m45m43m43m46m45m44m43m42m40m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$240.2m$208.2m$184.4m$185.3m$210.9m$232.1m$241.0m$207.9m$197.3m$177.2m
Capital spending−$20.0m−$15.7m−$3.7m−$6.4m−$64,000−$102.9m−$237.2m−$147.6m−$175.3m−$367.0m
Free cash flow$220.3m$192.4m$180.7m$179.0m$210.8m$129.3m$3.8m$60.2m$22.0m−$189.8m
Dividends paid−$169.7m−$156.5m−$156.2m−$161.8m−$182.9m−$194.6m−$179.7m−$165.4m−$153.0m−$138.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$121.3m$115.9m$106.5m$89.8m$90.7m$89.3m$85.8m$82.9m
Operating income$86,000$52.4m$50.2m$44.1m$48.7m$47.9m$42.9m$46.5m
Net income$55.6m$40.1m$38.2m$32.9m$37.0m$34.2m$43.2m$28.5m
Diluted earnings per share1.150.830.810.700.790.730.950.63
Cash from operations$64.0m$53.0m$69.0m$62.0m$61.0m$46.0m$57.0m$48.0m
Capital spending−$2.0m−$2.0m−$10.0m−$5.0m−$2.0m−$2.0m−$6.0m−$4.0m
Free cash flow$62.0m$51.0m$59.0m$57.0m$59.0m$44.0m$51.0m$44.0m
Total assets$2.96bn$2.89bn$2.80bn$2.69bn$2.70bn$2.78bn$2.61bn$2.46bn
Cash and short-term investments$30.4m$24.9m$19.6m$81.6m$18.6m$135.0m$24.3m$15.6m
Debt—$1.27bn$1.29bn$1.21bn$1.50bn$1.71bn$1.48bn$1.46bn
Shareholders' equity$1.57bn$1.51bn$1.52bn$1.48bn$1.48bn$1.43bn$1.37bn$1.23bn

Financial ratios

Data as of 22 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating margin52.3%57.5%59.4%38.8%53.6%70.6%——
Net margin37.6%41.2%42.4%23.9%37.4%55.6%——
Return on equity9.3%10.1%10.8%5.1%7.4%12.2%——
Return on assets5.1%5.3%5.5%2.6%3.9%5.9%——
Free cash flow yield8.5%7.6%6.7%6.8%7.1%11.5%——
Revenue growth12.9%4.8%15.0%-6.9%-10.2%4.6%——
Earnings growth3.0%1.7%104.3%-40.6%-39.6%15.4%——
Current ratio2.48x0.96x1.16x5.43x7.20x4.99x——
Debt to equity0.71x0.84x1.10x1.21x0.87x1.29x——
Equity ratio54.4%52.3%50.4%51.4%53.4%48.8%——
Interest coverage3.45x3.43x3.42x2.54x3.33x4.44x——
R&D as a share of sales——0.0%0.0%0.0%0.0%0.0%0.0%
Buybacks as a share of market value-3.6%-4.7%0.0%5.4%-2.2%-1.2%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue10.8%2.6%5.2%
Operating income20.9%-2.8%1.7%
Net income28.9%-5.1%-0.5%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin53.1%50.9%55.5%61.8%
Net margin39.3%36.8%40.1%46.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings25.322.817.934.123.616.822.520.819.819.6
Price to sales9.59.47.68.28.89.311.410.911.311.9

Market value over time

30 Nov 2016 to 21 Oct 2026, in USD

$2.83bn$3.15bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return14%20%4%-0%-20%-15%3%3%2%22%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.